Clavis Pharma and Clovis Oncology Sign Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126
Clavis Pharma to receive up to $380 million in staged payments, including a $15 million signing fee, and tiered double-digit royalties on sales
25-Nov-2009 -
Clavis Pharma ASA and Clovis Oncology, Inc. announced an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer. CP-4126 is a patented, lipid-conjugated form of the anti-cancer drug ...
Expression
pancreatic cancer